American Herbal Products Association (AHPA) > Resources > Regulations > Government Advocacy

Recent AHPA Advocacy

USDA’s final rule for GMO labeling ignores recommendations of consumers and AHPA

Final rule hinders consumer access to information on genetically modified foods

The U.S. Department of Agriculture (USDA) Agricultural Marketing Service (AMS) issued a final rule on December 20 that establishes the new national mandatory bioengineered (BE) food disclosure standard. The final rule does not incorporate significant revisions recommended by AHPA and consumer groups that were aimed at ensuring U.S. consumers can discern if their food includes genetically modified organisms (GMOs) or ingredients derived from GMOs.

Hemp-CBD Status Report and Webinar

Learn how passage of the Farm Bill impacts hemp and CBD companies

Congress passed a Farm Bill in 2018 that included historic provisions to legalize hemp, the low THC cultivars of the Cannabis sativa L. species. This landmark legislation changes how hemp and hemp-derived products like cannabidiol (CBD) are regulated in the U.S. To help the herbal products industry understand the new regulatory landscape, AHPA has produced a Status Report and webinar to answer industry questions.

Nutritional supplements access preserved in Arizona

AHPA and NPA protect proper rules for safe, legal, natural products

A proposal that would have drastically limited access to safe, legal and popular products for Arizonans was changed recently thanks to the Natural Products Association (NPA) and the American Herbal Products Association (AHPA), who worked with the Arizona Board of Pharmacy and other state policymakers on the issue.

Dietary Supplements Regulatory Summit

Hosted by AHPA, CHPA, CRN, NPA and UNPA

This one-day regulatory summit will feature updates and insights from FDA and industry regulatory experts, and will focus on the key regulatory compliance issues facing the dietary supplements industry.
Lessons in herb safety from The Cleveland Clinic Chinese Herbal Medicine Program

Lessons in herb safety from The Cleveland Clinic Chinese Herbal Medicine Program

Clinic reports only six mild adverse events since 2014

Nationally board-certified acupuncturist and Chinese herbalist at the Cleveland Clinic Galina Roofener shared safety data and lessons learned from the Cleveland Clinic Wellness Institute’s Traditional Chinese Herbal Medicine (TCHM) Program at her keynote delivered at the American Herbal Products Association’s (AHPA’s) 7th Annual Botanical Congress presented on Nov. 10 in Las Vegas at the SupplySide West trade show.
FDA Update by ODSP Director Steven Tave Presented at 7th Annual AHPA Botanical Congress

FDA Update by ODSP Director Steven Tave Presented at 7th Annual AHPA Botanical Congress

Tave outlines collaborations between FDA and supplement industry to ensure consumer safety

The American Herbal Products Association’s (AHPA’s) 7th Annual Botanical Congress featured a Food and Drug Administration (FDA) update by Steven Tave, FDA’s Director of the Office of Dietary Supplement Programs (ODSP), who highlighted recent collaborations between the responsible supplement industry and FDA toward the shared goal of a well-regulated dietary supplement market.
AHPA Chief Science Officer presents at Hemp Industries Association 25th Annual Conference

AHPA Chief Science Officer presents at Hemp Industries Association 25th Annual Conference

Dr. Johnson discusses quality standards for farmers, formulators, and finished product manufacturers

AHPA Chief Science Officer Dr. Holly Johnson discussed quality standards for hemp farmers, formulators, and finished product manufacturers at the Hemp Industries Association (HIA) 25th Annual Conference held Nov. 2-5 in Los Angeles.

Dietary Supplement Trade Associations Warn Consumers of Dangerous Substance Illegally Posing as a Dietary Supplement

Supplement industry sounds the alarm about the dangers of “phenibut,” a substance being illegally marketed in products fraudulently labeled as dietary supplements

Developed and used as a drug in the former Soviet Union for its supposed brain-enhancing properties, phenibut is not approved as a drug in the United States, nor does it meet the regulatory requirements to be sold in, or as, a dietary supplement. The ingredient should be considered dangerous, and has been associated with potentially serious side effects and great risk for addiction.

AHPA launches sustainability subcommittee, formalizing ongoing efforts

Subcommittee to further AHPA’s ongoing efforts to ensure sustainable supplies of valuable botanicals

AHPA's Botanical Raw Materials Committee has launched a Sustainability Subcommittee to further AHPA’s ongoing efforts to ensure sustainable supplies of valuable botanicals. The subcommittee will be a vehicle for increasing awareness of sustainability issues and best practices, provide a forum to discuss and develop industry-wide standards, and promote existing sustainability initiatives throughout the industry.

Arizona Board of Pharmacy reportedly considers most dietary supplements to be nonprescription drugs

Board is pushing supplement companies that sell in the state to register as "wholesaler of nonprescription drugs"

The Arizona State Board of Pharmacy recently began interpreting its authority in a manner that implies that virtually every company that manufacturers or sells dietary supplements in the state will need to register as a nonprescription drug facility. If the board is successful and persistent in this approach, it could significantly disrupt dietary supplement business in the state.
RSS
12345678910 Last

2019 Annual Fund Sponsors

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.